Skip to main content
. 2023 May 26;22:165. doi: 10.1186/s12936-023-04600-8

Table 3.

Dissolution test results of artemether–lumefantrine samples (N = 74) collected from low and high malaria transmission settings in Uganda, June–December 2021

Brand name Artemether label claim (mg) Number of samples tested
n (%)
Artemether within pharmacopeial limit, 70%
Pass/Fail
Lumefantrine within pharmacopeial limit, 60%
Pass/Fail
LONART 20/120 20 (27%) Pass Pass
40/240 1 (1.4%) Pass Pass
80/480 3 (4.1%) Pass Pass
LONART-DS 80/480 1 (1.4%) Pass Pass
ARTEFAN 20/120 12 (16.2%) Pass Pass
40/240 1 (1.4%) Pass Pass
60/360 1(1.4%) Pass Pass
80/480 1(1.4%) Pass Pass
LUMARTEM 20/120 2 (2.7%) Pass Pass
80/480 1 (1.4%) Pass Pass
CO-METHER 20/120 5 (6.8%) Pass Pass
KOMEFAN-140 20/120 1 (1.4%) Pass Pass
COMBIART 20/120 5 (6.8%) Pass Pass
LUMERAX 20/120 1 (1.4%) Pass Pass
LARIACT 20/120 3 (4.1%) Pass Pass
Cach-ART 20/120 2 (2.7%) Pass Pass
LUMAREN 20/120 2 (2.7%) Pass Pass
COARTEM 20/120 1 (1.4%) Pass Pass
KOMEFAN 20/120 1 (1.4%) Pass Pass
LUMITER 20/120 6 (8.1%) Pass Pass
Not Indicateda 20/120 4 (5.4%) Pass Pass
Total number 74 (100%) 74 (100%) 74(100%)

aOne batch of samples with not brand name indicate (HWE111219) from a low malaria transmission setting had 68% artemether dissolution